| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | Garcia Vicién, Gemma |
| dc.contributor.author | Ruiz, Nuria |
| dc.contributor.author | Ruffinelli, Jose Carlos |
| dc.contributor.author | Mils, Kristel |
| dc.contributor.author | Bañuls, María |
| dc.contributor.author | Micke, Patrick |
| dc.contributor.author | Mezheyeuski, Artur |
| dc.date.accessioned | 2025-01-10T13:35:39Z |
| dc.date.available | 2025-01-10T13:35:39Z |
| dc.date.issued | 2024-12-04 |
| dc.identifier.citation | Garcia-Vicién G, Ruiz N, Micke P, Ruffinelli JC, Mils K, Bañuls M, et al. The histological growth patterns in liver metastases from colorectal cancer display differences in lymphoid, myeloid, and mesenchymal cells. MedComm. 2024 Dec;5(12):e70000. |
| dc.identifier.issn | 2688-2663 |
| dc.identifier.uri | https://hdl.handle.net/11351/12395 |
| dc.description | Desmoplasia; Hepatic metastases; Histologic growth pattern |
| dc.description.abstract | Colorectal liver metastases grow following different histologic growth patterns (HGPs), classified as desmoplastic and nondesmoplastic (dHGP, non-dHGP), being the latter associated with worst prognosis. This study aimed to investigate the tumor microenvironment (TME) between HGPs supporting different survival. Multiplexed immunohistochemical staining was performed with the Opal7 system in a 100-patients cohort to evaluate the tumor–liver interface with three different cell panels: lymphoid, myeloid, and carcinoma-associated fibroblasts. Differences between HGPs were assessed by Mann–Whitney U test with Pratt correction and Holm–Bonferroni multitest adjustment. Cytotoxic T-cells were more abundant in tumoral areas of dHGP, while non-dHGP had higher macrophages infiltration, Th2, CD163+, and Calprotectin+ cells as well as higher pSMAD2 expression. Regarding carcinoma-associated fibroblasts, several subsets expressing COL1A1 were enriched in dHGP, while αSMAlow_single cells were present at higher densities in non-dHGP. Interestingly, Calprotectin+ cells confer better prognoses in non-dHGP, identifying a subgroup of good outcome patients that unexpectedly also show an enrichment in other myeloid cells. In summary, our results illustrate different TME landscapes with respect to HGPs. dHGP presents a higher degree of immunocompetence, higher amounts of Collagen 1 as well as lesser presence of myeloid cell populations, features that might be influencing on the better prognosis of encapsulated metastases. |
| dc.language.iso | eng |
| dc.publisher | Wiley |
| dc.relation.ispartofseries | MedComm;5(12) |
| dc.rights | Attribution 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
| dc.source | Scientia |
| dc.subject | Prognosi |
| dc.subject | Metàstasi |
| dc.subject | Còlon - Càncer |
| dc.subject | Recte - Càncer |
| dc.subject | Fetge - Càncer |
| dc.subject.mesh | Neoplasm Metastasis |
| dc.subject.mesh | Colorectal Neoplasms |
| dc.subject.mesh | Tumor Microenvironment |
| dc.subject.mesh | Liver Neoplasms |
| dc.subject.mesh | Prognosis |
| dc.title | The histological growth patterns in liver metastases from colorectal cancer display differences in lymphoid, myeloid, and mesenchymal cells |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1002/mco2.70000 |
| dc.subject.decs | metástasis neoplásica |
| dc.subject.decs | neoplasias colorrectales |
| dc.subject.decs | microambiente tumoral |
| dc.subject.decs | neoplasias hepáticas |
| dc.subject.decs | pronóstico |
| dc.relation.publishversion | https://doi.org/10.1002/mco2.70000 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Garcia-Vicién G] Tumoural and Stromal Chemoresistance Group, Oncobell Program, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. [Ruiz N] Tumoural and Stromal Chemoresistance Group, Oncobell Program, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. Department of Pathology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain. [Micke P] Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. [Ruffinelli JC] Tumoural and Stromal Chemoresistance Group, Oncobell Program, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. Department of Medical Oncology, Institut Català d’Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain. [Mils K] Tumoural and Stromal Chemoresistance Group, Oncobell Program, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. Department of Surgery, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain. [Bañuls M] Program Against Cancer Therapeutic Resistance (ProCURE), Institut Català d’Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain. [Mezheyeuski A] Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
| dc.identifier.pmid | 39563958 |
| dc.identifier.wos | 001369933000001 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |